A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
Terminated · Phase 1 · NCT05712278
Conditions: Acute Myeloid Leukaemia
At a glance
- Research payments reported, 2025
- $48,186
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 7
About the trial
- Sponsor
- Sanofi
- Tested
- SAR445419 (drug), fludarabine (drug), cytarabine (drug)
- Dates
- Started 2023-06-16; completion 2024-03-12
- Results posted
- Not yet
This is a single group, Phase 1, single-arm, dose escalation study to determine the candidate dose(s), and evaluate safety, tolerability, and preliminary anti-tumor activity of SAR445419 administered after fludarabine and cytarabine conditioning for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). Adult participants with R/R AML will be eligible for treatment. The study is intended to assess the candidate dose(s) by the occurrence of dose-limiting toxicity (DLT) from start of chemotherapy until 28 days after the first administration of SAR445419. The duration of the study for a participant will include: * Screening period up to 21 days prior to initiating chemothe…
From ClinicalTrials.gov, last updated 2026-06-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $48,186 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Biomedical Research Alliance of New York LLC $48,186
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.